Mumakore achangopfuura, kurapwa kwekufutisa uye Type 2 chirwere cheshuga kwave nekufambira mberi kwekuchinja. Kutevera GLP-1 receptor agonists (semuenzaniso, Semaglutide) uye maviri agonists (semuenzaniso, Tirzepatide),Retatrutide(LY3437943), akatatu agonist(GLP-1, GIP, uye glucagon receptors), yakaratidza kushanda kusati kwamboitika. Nemhedzisiro inoshamisa mukudzikisira uremu uye kuvandudzwa kwemetabolism, inoonekwa seyangangoita kurapa kwezvirwere zvemetabolism.
Nzira Yekuita
-
GLP-1 receptor activation: Inowedzera insulin secretion, inodzvinyirira kudya, inononoka kubuda kwegastric.
-
GIP receptor activation: Inowedzera glucose-kudzikisa mhedzisiro yeGLP-1, inovandudza insulin senitivity.
-
Glucagon receptor activation: Inosimudzira kushandiswa kwesimba uye mafuta metabolism.
Iyo synergy yeaya matatu receptors inobvumira Retatrutide kudarika zvinodhaka zviripo mune zvese uremu uye glycemic control.
Clinical Trial Data (Chikamu II)
Mune aPhase II kuyedza ne338 overweight / obese varwere, Retatrutide yakaratidza migumisiro inovimbisa zvikuru.
Tafura: Kuenzaniswa kweRetatrutide vs. Placebo
| Dose (mg/vhiki) | Kuderedza Kurema (%) | HbA1c Kuderedza (%) | Zviitiko Zvakaipa Zvakawanda |
|---|---|---|---|
| 1 mg | -7.2% | -0.9% | Nausea, kurutsa zvishoma |
| 4 mg | -12.9% | -1.5% | Nausea, kurasikirwa kwechido |
| 8 mg | -17.3% | -2.0% | GI kusagadzikana, nyoro manyoka |
| 12 mg | -24.2% | -2.2% | Nausea, kurasikirwa kwechido, kuvimbiswa |
| Placebo | -2.1% | -0.2% | Hapana shanduko yakakosha |
Data Visualization (Kuderedza Weight Kuenzanisa)
Iyo inotevera bar chart inoratidzaavhareji kuderedza uremumumhando dzakasiyana dzeRetatrutide zvichienzaniswa ne placebo:
Nguva yekutumira: Sep-16-2025